SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Prologis priced a ¥44.7 billion (~$280.6 million) offering of senior unsecured notes in three tranches (2030, 2035, and 2041 maturities) on June 4, 2026, with closing expected June 11, 2026. The proceeds will be used for debt repayment and general corporate purposes.
View raw filing on EDGAR →This disclosure furnishes preliminary assets under management (AUM) as of May 31, 2026 via a news release under Regulation FD. While AUM is a key operational metric for asset managers and would be material to investors assessing the registrant's business performance and client flows, it does not fit neatly into the more specific event categories (it is not an earnings release, M&A activity, executive change, or other defined event type). The disclosure is material but best classified as other_material.
View raw filing on EDGAR →The filing discloses an update on a previously-announced merger between TMTG and TAE Technologies, Inc., with a press release issued on June 10, 2026 providing material transaction details. The disclosure references a Form S-4 registration statement, proxy statement/prospectus, and merger agreement, all hallmarks of a material acquisition/change of control transaction that would substantially affect the registrant's business and capital structure.
View raw filing on EDGAR →Nuwellis announced the closing of a registered public offering that raised approximately $6,000,000 in gross proceeds and resulted in the exercise of pre-funded warrants, increasing outstanding shares to 12,750,321. This is a material equity issuance that dilutes existing shareholders and signals capital-raising activity typical of small-cap companies under financial pressure.
View raw filing on EDGAR →At the 2026 annual meeting of stockholders held on June 9, 2026, the Company's stockholders approved an amendment to the Amended and Restated 2010 Stock Incentive Plan to increase the aggregate number of authorized shares by 6,500,000 for employee compensation purposes.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Taboola's Annual General Meeting held on June 9, 2026. The filing reports voting outcomes on five proposals: director re-elections, advisory compensation vote, compensation policy approval, CEO compensation terms, and auditor re-appointment. All proposals passed by requisite majorities, making this a material governance event that affects investor understanding of shareholder approval and corporate oversight.
View raw filing on EDGAR →PCSC shareholders voted on June 10, 2026 to approve an amendment to the articles of association extending the deadline for completing an initial business combination from June 13, 2026 to June 13, 2027. The Extension Amendment Proposal passed with overwhelming support (8,515,798 for, 75 against, 4,866 abstain) at a quorum of 76.5% of voting power.
View raw filing on EDGAR →John Gehre was appointed as Chairman of the Board effective June 9, 2026. The appointment represents a material change to the company's governance and leadership structure.
View raw filing on EDGAR →Shareholders voted at the June 9, 2026 annual meeting on three proposals: election of six directors, ratification of Whitley Penn as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of a special stockholder meeting held on June 10, 2026, where Kennedy-Wilson shareholders voted on three proposals: (1) adoption of the Merger Agreement with Kona Bidco, LLC (approved with 148,957,598 votes for vs. 535,978 against), (2) advisory compensation approval (approved 139,504,118 for vs. 9,411,306 against), and (3) adjournment proposal (approved 143,306,344 for vs. 6,169,767 against). The merger proposal approval is material as it enables the anticipated June 16, 2026 closing of a change-of-control transaction.
View raw filing on EDGAR →The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of CME Group's 2026 Annual Meeting of Shareholders held on June 9, 2026 (reconvened from May 14 due to quorum issues). The filing details voting outcomes on five substantive proposals: elimination of Class B-1, B-2, and B-3 director election rights (Items 4–6); a certificate of incorporation amendment (Item 7); and election of Class B directors (Item 8). The disclosure includes vote tallies, percentages, and quorum determinations across multiple share classes, which is the core content of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 4, 2026 annual meeting of stockholders, covering three proposals: election of six directors, ratification of KPMG as independent auditors, and an advisory vote on executive compensation. The filing presents detailed vote tallies for each matter, which is the core content of Item 5.07 and constitutes a material event affecting corporate governance and board composition.
View raw filing on EDGAR →Ketan Seth resigned as Chief Executive Officer and director of Blue Acquisition Corp effective immediately on June 9, 2026. While the filing also discloses David Bauer's appointment as interim CEO on the same day, the principal disclosed action centers on the CEO's departure. For a SPAC, CEO resignation is material to investors assessing management continuity and the company's ability to identify and consummate a business combination.
View raw filing on EDGAR →The filing discloses J.Jill's financial results for the first quarter ended May 2, 2026, via a press release attached as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the canonical disclosure vehicle for earnings releases and would materially affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →Cullinan Therapeutics disclosed updated Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, along with initial Phase 1b/2a data for velinotamig in SLE, demonstrating positive efficacy and safety signals including clinical remission in RA patients and rapid improvements in SLE biomarkers. This clinical progress represents material advancement of the company's pipeline that would affect a reasonable investor's assessment of the company's valuation and strategic direction.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Strategy Inc's 2026 Annual Meeting of Stockholders held on June 8, 2026, including voting outcomes on five proposals: election of eight directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, ratification of preferred stock certificate amendments, and approval of dividend payment frequency changes. The detailed vote tallies (For/Against/Abstain/Broker Non-votes) for each proposal are the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →Fold Holdings disclosed a material transaction involving the monetization of $45 million in bitcoin and elimination of $20 million in debt, which would affect a reasonable investor's assessment of the company's liquidity, asset position, and leverage. While this does not fit neatly into the standard M&A, impairment, or covenant categories, the scale and nature of the transaction (significant asset liquidation and debt reduction) constitute a material event requiring disclosure under Regulation FD.
View raw filing on EDGAR →The filing discloses preliminary results from Medallion Financial Corp.'s 2026 Annual Meeting of Stockholders via press release. This is a direct disclosure of shareholder voting outcomes, which is material to investors as it determines board composition, executive compensation approvals, and other governance matters. The event matches the shareholder_vote_results taxonomy entry.
View raw filing on EDGAR →The disclosure announces the expiration and final results of debt exchange offers and consent solicitations by Qwest/Lumen to exchange approximately $2 billion in outstanding notes (2056 and 2057 notes) for new notes with shorter maturities (2051 and 2052). While this involves debt restructuring, it does not fit cleanly into the "ma_activity" category (which typically covers acquisitions, dispositions, mergers, or changes of control) nor does it constitute a covenant breach, restatement, or other more specific event type. The exchange offer completion is material to investors as it affects the company's debt structure and maturity profile, but the specific event—completion of a debt exchange offer—lacks a dedicated taxonomy category.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from QNB Corp.'s June 9, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes on three proposals: election of Class II directors (Bergman, Bimes, Brown, and Stauffer), approval of the 2026 Employee Stock Purchase Plan, and ratification of Baker Tilly US, LLP as independent auditor. All proposals passed with substantial majorities, making this a material governance event that investors rely on to confirm board composition and audit oversight.
View raw filing on EDGAR →National Fuel Gas Company disclosed the offering and sale of $1.5 billion in aggregate principal amount of senior notes across three tranches (2029, 2031, and 2036 maturities) with rates ranging from 4.75% to 5.50%. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial obligations, it does not fit cleanly into the "dilutive_issuance" category (which focuses on equity securities) or "ma_activity" (which addresses acquisitions, dispositions, or changes of control). The disclosure is material but represents a debt financing event that falls outside the more specific taxonomy categories.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for two proposals: election of Class II directors (H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.) and ratification of PricewaterhouseCoopers LLP as independent auditor. Both proposals passed with strong majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.
View raw filing on EDGAR →The Board approved a 2026 Common Share Repurchase Program authorizing up to 500,000 shares with a maximum aggregate purchase price of $15,000,000. While share repurchase programs are routine capital allocation decisions, this authorization is material to investors as it signals management's confidence in valuation, affects share count and EPS calculations, and represents a significant deployment of capital. The disclosure does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →IDEAYA completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 additional shares, raising approximately $323.6 million in net proceeds. This is a material dilutive equity issuance disclosed under Item 8.01, representing a substantial increase in shares outstanding and capital raise that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →Oracle issued a press release on June 10, 2026 announcing financial results for its fiscal fourth quarter ended May 31, 2026, disclosing quarterly financial performance and results of operations.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Amplitude's 2026 annual meeting of stockholders held on June 9, 2026. The filing presents voting results for three proposals: election of Class II directors (Pat Grady, Curtis Liu, Catherine Wong), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core content of the disclosure.
View raw filing on EDGAR →Syndax Pharmaceuticals held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on five proposals: election of directors (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, and approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. All proposals passed.
View raw filing on EDGAR →Elizabeth S. Perkins, the Company's Senior Vice President and Chief Financial Officer, was appointed to the additional role of principal accounting officer on June 10, 2026, succeeding Rachel Labrecque who passed away on June 9, 2026. While the disclosure involves a departure (Labrecque's death), the principal disclosed action is Perkins' appointment to a key accounting role, making exec_appointment the most salient classification. The appointment of a principal accounting officer is material to investors as it affects financial reporting oversight and governance.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MarketAxess Holdings' 2026 Annual Meeting of Stockholders held on June 10, 2026, filed under Item 5.07. The filing reports voting outcomes for four proposals: election of 12 directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation ("say-on-pay"), and a stockholder proposal regarding special meeting rights. All proposals passed with substantial majorities. This is material as it reflects shareholder approval of governance and compensation matters.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Aimco's 2026 Annual Meeting of Stockholders held on June 10, 2026, covering three proposals: election of nine directors, ratification of Grant Thornton LLP as independent auditor, and advisory approval of executive compensation. The detailed tabulation of votes for and against each proposal is the core disclosure required under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst & Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.
View raw filing on EDGAR →The filing discloses the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. While the disclosure also includes compensatory arrangements (annual retainer of $50,000 and an option grant of 85,937 shares), the principal action is the appointment itself. The appointment of a new director is material to investors as it affects board composition and governance.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Exzeo Group's Annual Meeting of Shareholders held on June 9, 2026. The filing reports voting outcomes for two proposals: (1) election of two Class A directors (Paresh Patel and Irene Hurst) and (2) ratification of Forvis Mazars, LLP as independent auditor. The specific vote tallies (For, Against, Withheld, Abstained) are provided for each matter, which is the hallmark of Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →Dr. Anna Eramo, Chief Medical Officer, resigned effective June 15, 2026, and will transition to an advisor role. While the filing emphasizes that her departure is not expected to materially impact clinical development activities, the resignation of a CMO at a clinical-stage pharmaceutical company is a material executive departure that investors would consider significant. The separation agreement with severance and equity acceleration further confirms this is a formal executive departure event.
View raw filing on EDGAR →Dell Technologies entered into a $6 billion senior unsecured revolving credit facility on June 10, 2026, replacing an existing credit agreement. This refinancing arrangement materially affects the company's liquidity and capital structure, though it does not constitute an M&A transaction or change of control.
View raw filing on EDGAR →Stockholders approved six proposals at the Annual Meeting on June 10, 2026, including election of directors, ratification of auditors, approval of a Series B convertible preferred stock issuance that triggers a change of control under Nasdaq rules, authorization of additional common shares, and approval of equity compensation plans.
View raw filing on EDGAR →Northern States Power Company-Wisconsin entered into a Bond Purchase Agreement for $250 million in First Mortgage Bonds due 2041, representing a material debt issuance that affects the company's capital structure and financial obligations.
View raw filing on EDGAR →The company entered into a material definitive agreement disclosed under Item 1.01, though the specific nature of the agreement (whether M&A activity, significant contract, or other transaction) cannot be determined without the full filing text.
View raw filing on EDGAR →Fifth Third Bancorp completed a material debt restructuring involving exchange offers and consent solicitations on June 10, 2026, exchanging approximately $1.27 billion in Comerica-issued notes (assumed by FTFC) for new Fifth Third Bancorp notes while eliminating significant covenants and events of default from the original indentures. This is a material capital structure event affecting the company's debt obligations and financial flexibility, but does not fit neatly into the more specific categories (not an M&A activity, impairment, or covenant breach—rather a proactive refinancing and covenant elimination). The elimination of restrictive covenants and events of default is particularly significant to investors assessing financial risk.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class I directors (Robert Gries, Andrew Wright, and Beth W. Bruce) and (ii) ratification of Forvis Mazars, LLP as independent auditor. The tabulated vote counts for each proposal are provided, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →WhiteHawk Minerals Corp. completed a material internalization transaction in which WhiteHawk OpCo acquired all outstanding equity interests in ManagementCo from the Management Contributor for 3,750,000 common units and Class B shares valued at $97.5 million (75% of a $130 million Internalization Price), with an additional earnout of up to $32.5 million contingent on EBITDA targets. This acquisition transforms the Company from externally managed to internally managed and is accompanied by entry into material definitive agreements including a Contribution Agreement, Amended and Restated Limited Partnership Agreement, and Registration Rights Agreement.
View raw filing on EDGAR →WhiteHawk Minerals issued 3,750,000 shares of Class B Common Stock to the Management Contributor in connection with the internalization transaction, relying on Section 4(a)(2) exemption from registration. This unregistered private placement of equity securities materially dilutes existing shareholders and affects the company's ownership structure and capitalization.
View raw filing on EDGAR →WhiteHawk Minerals Corp. completed its initial public offering on June 10, 2026, raising approximately $200.2 million in gross proceeds from the sale of 7.7 million shares at $26.00 per share, with listing on the NYSE under ticker 'WHK.' This transformative capital-raising event materially affects the company's capitalization and public market status.
View raw filing on EDGAR →WhiteHawk Minerals appointed four key officers effective upon closing of the offering: Daniel Herz as CEO and President, Jeffrey Slotterback as CFO/Treasurer/Secretary, Stephen Pilatzke as Chief Accounting Officer, and Michael Downs as COO. These material C-suite appointments reflect the company's transition to internal management in connection with its public offering.
View raw filing on EDGAR →